THE FIRST-AND-ONLY BISPECIFIC ANTIBODY APPROVED FOR BOTH 3L+ DLBCL AND 3L+ FL1

Choose an indication:

Granted accelerated approvals based on overall response
rate and durability of response. Continued approval for these
indications may be contingent upon verification and
description of clinical benefit in confirmatory trials.